| Acceptance rate | 46% |
|---|---|
| Time to first decision | 20 days* |
| Time to decision with review | 50 days* |
*Approximate number of days
**The days mentioned above are averages and do not indicate exact durations. The process may vary for each article.
ACTA Pharmaceutica Sciencia
2023 , Vol 61 , Num 4
New timed-release tablets of montelukast sodium for the treatment of nocturnal bronchial asthma
1 Department of Pharmaceutics, C.L.Baid Metha College of Pharmacy, Pharmaceutics, Chennai,Tamil Nadu, India2 M.A.M. College of Pharmacy, Pharmaceutics, Narasaraopet, Andhra Pradesh, 522601, India
3 Department of Pharmacology, National Institute of Siddha, Chennai - 600 047, Tamil Nadu, India
DOI : 10.23893/1307-2080.APS6122 Montelukast compressed tablets were prepared by dry blending of excipients and direct compression. The inner layer containing 3 mg of Montelukast to provide a burst release at 6.5 h. A sustained-release layer consisting of 7 mg and different proportions of HPMC K4M was used to optimise the formulation. The different drug: layer ratio, from 3:7 to 5:5 used for F1 to F10 batch, but 20 % of HPMC K4M (F5) with the layer ratio of 3:7, gave the desired release profile within 8 h and achieved burst release from the immediate release layer in 6.5 h. The swelling and erosion properties of optimised formulation were investigated at different pH. In vivo pharmacokinetic studies in rabbits confirmed the sustained release with an average T max value at 10 h and C max value of 478.32 ng/mL compared to the conventional tablet, as C max was 490.10 ng/mL attained by 2 h (T max). Keywords : Bronchial asthma, chronotherapy, Montelukast sodium, timed-release preparation